uniQure N.V. (NASDAQ:QURE) Insider Sells $20,406.72 in Stock

uniQure N.V. (NASDAQ:QURE - Get Free Report) insider Walid Abi-Saab sold 1,466 shares of the company's stock in a transaction dated Friday, June 27th. The stock was sold at an average price of $13.92, for a total transaction of $20,406.72. Following the completion of the sale, the insider directly owned 150,437 shares of the company's stock, valued at $2,094,083.04. The trade was a 0.97% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

uniQure Stock Performance

Shares of QURE stock traded up $0.21 during trading on Friday, reaching $14.49. 328,148 shares of the company's stock traded hands, compared to its average volume of 1,960,399. The firm's 50-day moving average is $14.53 and its 200 day moving average is $13.98. The company has a market capitalization of $793.49 million, a P/E ratio of -3.30 and a beta of 0.08. uniQure N.V. has a 1 year low of $3.73 and a 1 year high of $19.18. The company has a current ratio of 11.99, a quick ratio of 11.99 and a debt-to-equity ratio of 1.53.

uniQure (NASDAQ:QURE - Get Free Report) last posted its earnings results on Friday, May 9th. The biotechnology company reported ($0.82) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.07) by $0.25. The firm had revenue of $1.57 million for the quarter, compared to the consensus estimate of $5.93 million. uniQure had a negative return on equity of 483.87% and a negative net margin of 1,077.05%. Equities research analysts expect that uniQure N.V. will post -3.75 EPS for the current year.

Analysts Set New Price Targets

Several research firms have recently issued reports on QURE. Guggenheim reaffirmed a "buy" rating and issued a $28.00 target price on shares of uniQure in a report on Monday, May 12th. HC Wainwright reaffirmed a "buy" rating and set a $70.00 target price on shares of uniQure in a research report on Thursday, May 29th. Chardan Capital reiterated a "buy" rating and set a $38.00 target price on shares of uniQure in a research note on Friday, May 30th. Cantor Fitzgerald upgraded shares of uniQure to a "strong-buy" rating in a research report on Monday, May 19th. Finally, Wall Street Zen lowered shares of uniQure from a "hold" rating to a "sell" rating in a research report on Saturday, June 14th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $37.82.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Invesco Ltd. lifted its holdings in shares of uniQure by 453.2% in the fourth quarter. Invesco Ltd. now owns 613,601 shares of the biotechnology company's stock worth $10,836,000 after buying an additional 502,684 shares in the last quarter. Oppenheimer & Co. Inc. bought a new stake in uniQure during the 4th quarter worth approximately $320,000. Assenagon Asset Management S.A. lifted its stake in uniQure by 355.2% in the 1st quarter. Assenagon Asset Management S.A. now owns 334,894 shares of the biotechnology company's stock worth $3,550,000 after purchasing an additional 261,323 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in uniQure in the 4th quarter worth approximately $1,951,000. Finally, Northern Trust Corp boosted its holdings in uniQure by 2.1% in the 4th quarter. Northern Trust Corp now owns 95,591 shares of the biotechnology company's stock valued at $1,688,000 after purchasing an additional 1,923 shares during the period. Institutional investors own 78.83% of the company's stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.